Aug 10,2023

Senseonics Holdings, Inc. Reports Second Quarter 2023 Financial Results

Senseonics Holdings today reported financial results for the quarter ended June 30, 2023. Senseonics reported revenue of $4.1 million in the second quarter of 2023 compared to $3.7 million for the second quarter of 2022. U.S. revenue was $1.8 million in the second quarter of 2023 compared to $1.2 million in the prior year period, and revenue outside the U.S. was $2.3 million in the second quarter of 2023 compared to $2.5 million in the prior year period. Senseonics reiterates the expectation for full year 2023 global net revenue to be in the range of $20 million to $24 million. The company has also submitted an application to the FDA for an iCGM designation for the Eversense CGM system and received a positive coverage decision from UnitedHealthcare over the Q2 2023.

View Analyst & Ambassador Comments
Go to original news
Aug 10,2023

Ultrahuman Ring Air review

Indian fitness and nutrition tracking startup Ultrahuman has fast-followed its debut smart ring last year with a second generation of the device — which officially launched in June. Ultrahuman’s smart ring is designed to sit alongside its CGM-powered program; either as a standalone sleep & fitness tracker (with the bonus ability to dish some dietary insights, if you log what you’re eating in the companion app, powered by aggregated data from a metabolic health tracking program called Cyborg users); or as a complement to the fully fledged metabolic health tracking program.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 10,2023

DarioHealth Reports Second Quarter 2023 Financial and Operating Results

DarioHealth today reported financial results for the second quarter 2023 and provided a corporate and commercial update. Revenues for the second quarter ended June 30, 2023, were $6.15 million, a 0.5% decrease from $6.18 million for the second quarter ended June 30, 2022, and a decrease of 13% from $7.07 million for the first quarter of 2023. The decrease in revenues for the quarter ended June 30, 2023, as compared to the quarter ended June 30, 2022, resulted mainly from lower revenues from the Company's B2C Channel. Total operating expenses for the second quarter of 2023 were $16.1 million, compared with $18.5 million for the second quarter of 2022, and $15.6 million for the first quarter of 2023. Revenues for the six months ended June 30, 2023, were $13.2 million, a 7.2% decrease from $14.2 million for the six months ended June 30, 2022.

View Analyst & Ambassador Comments
Go to original news
Aug 09,2023 TOP STORY

Better Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

Better Therapeutics reported its net loss for the Q2 2023 as $7.6 million, compared to $9.9 million for the same period in 2022. Cash and cash equivalents were $6.2 million on June 30, 2023, compared to $15.7 million on December 31, 2022. In July 2023, the Company raised $6.7 million in net proceeds from additional financings, and announced that the FDA authorized AspyreRxTM (formerly BT-001), a prescription-only digital therapeutic (PDT) treatment indicated to provide cognitive behavioral therapy to patients 18 years or older with type 2 diabetes (T2D). Better Therapeutics completed final pricing research and set the list price for AspyreRx at $750.00 for a 90-day script. The Company also plans to offer the product on a cash-pay basis at a discounted price, for a limited period of time, with an affordable out-of-pocket option. AspyreRx is expected to launch commercially in the fourth quarter of 2023. On another note, following the successful completion of the LivVita Liver Study, Better Therapeutics intends to submit a request to the FDA for Breakthrough Device Designation for its investigational PDT in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) by the end of 2023.

View Analyst & Ambassador Comments
Go to original news
Aug 09,2023

Global Smart Insulin Pens Market Achieved a Total Market Size of $53.98 Billion in 2022, Witnessing Growth Driven by Advancements in Diabetes Management Technologies

The global insulin pen market is projected to achieve a significant milestone, reaching a value of US$ 73.39 Billion by 2028, with a steady compound annual growth rate (CAGR) of 5.25%, accordin to the research publisher. In 2022, the global smart insulin pens market achieved a total market size of US$ 53.98 Billion.

View Analyst & Ambassador Comments
Go to original news
Aug 08,2023

Dario Expands Partnership with Large Regional Health Plan

DarioHealth announced today the expansion of its agreement with a large regional health plan to deliver highly personalized digital health solutions to Plan members living with diabetes with the launch anticipated to be in the first quarter of 2024. The Plan is adding Dario's support for diabetes to complement the current solution in place for hypertension. Dario provides support for diabetes and hypertension as part of the Company's cardiometabolic product suite designed to address frequently co-occurring chronic health needs with integrated, holistic support.

PRODUCT

#coaching

#dtx

View Analyst & Ambassador Comments
Go to original news
Aug 08,2023

Insulet Reports Second Quarter 2023 Revenue Increase of 32% Year-Over-Year (32% Constant Currency)

Insulet Corporation today announced financial results for the three months ended June 30, 2023. Insulet reported the second quarter 2023 revenue of $396.5 million, up 32.4%, or 32.2% in constant currency, compared to $299.4 million in the prior year. Its Total Omnipod revenue of $380.5 million increased by 33.2%, or 33.0% in constant currency. The company's operating income was preorted as $31.1 million, or 7.8% of revenue, compared to operating loss of $26.7 million, or (8.9)% of revenue, in the prior year. Previously, Insulet has commercially launched Omnipod 5 in the United Kingdom, its first international Omnipod 5 launch, and submitted the Omnipod 5 iOS App for the iPhone to the FDA for 510(k) clearance.

View Analyst & Ambassador Comments
Go to original news
Aug 07,2023

Liva appoints new CCO & UK GM and CMO

Liva is pleased to welcome two new industry leaders, Sian Jarvis as Chief Marketing Officer and Karen O’Regan as Chief Commercial Officer and UK General Manager, to its executive team.

View Analyst & Ambassador Comments
Go to original news
Aug 07,2023

Insulin Delivery Devices Market is Expected to Reach $46.2 Billion

Insulin Delivery Devices market in terms of revenue was estimated to be worth $30.8 Billion in 2023 and is poised to reach $46.2 Billion by 2028, growing at a CAGR of 8.5% from 2023 to 2028 according to the publisher. Advances in technology have made it possible to create more flexible and sophisticated delivery devices. Government support and favourable reimbursement schemes are also driving market growth.

View Analyst & Ambassador Comments
Go to original news
Aug 04,2023

Continuous Glucose Monitoring Market to Cross USD 10.56 Bn by 2030

The Continuous Glucose Monitoring Market reached a valuation of USD 7.6 billion in 2022 according to the research publisher. It is projected to attain USD 10.56 billion by 2030, exhibiting a CAGR of 4.2% during the forecast period spanning from 2023 to 2030. As the global burden of diabetes continues to escalate, CGM systems will play a crucial role in improving glycemic control and reducing diabetes-related complications. Additionally, favorable reimbursement policies and a growing focus on remote healthcare solutions further amplify the market's potential.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES